Current Report according - Regulation no.5/2018
Date of the report: - 01.10.2018
Name of the issuer - ZENTIVA S.A.
Main seat: - Bd. Theodor Pallady nr.50, Bucuresti
Tel. /Fax no.: - 021-3047200 /021-345.40.04
Unique Code: - 336206
Registration No. - J40/363/1991
Shared capital - 41.696.115 RON
Capital market - Bucharest Stock Exchange
Significant events to be reported:
Zentiva SA informs that Zentiva Group issued a press release, notifying that starting today, October 1st, 2018, backed by one of the world’s largest and most experienced global private equity investors - Advent International, the generics manufacturer Zentiva marks its first day as an independent organization, following completion of the company’s previously announced divestment from Sanofi.
The press release can be found below:
Generics manufacturer Zentiva begins
operations as independent company
PRAGUE – October 1st, 2018 – Today marks generics manufacturer Zentiva’s first day as an independent organization, following completion of the company’s previously announced divestment from Sanofi.
Zentiva is headquartered in Prague, and the company – now backed by Advent International, one of the world’s largest and most experienced global private equity investors – is entering a new era of independence and transformation.
Patrick Aghanian, Head of Zentiva, believes that the divestment brings new opportunities for the company and its customers, resulting in a faster, more flexible and more agile business.
“Zentiva’s roots stretch back 530 years to the Black Eagle pharmacy, a small business on the castle side of Prague. We are very proud of our heritage and we look forward to expanding and building our footprint in Generics and OTC medicines across Europe. This heritage not only strengthens our resolve to remain customer-focused, it also drives our future priorities as we strive to improve healthcare with a more personalized approach. We aspire that healthcare should be a right and not a privilege, and that healthcare solutions should be accessible to as many people as possible.”
“We want to build a reputation that is synonymous with value in the eyes of our partners,” he continues. “Standing side-by-side with healthcare professionals, pharmacists and Health System decision-makers, we have the same sense of social obligation to help lower costs and improve access to healthcare. We strive to support people’s daily healthcare needs.”
Patrick adds that this latest chapter in the company’s history is also positive news for employees: “The intended growth of our organization brings new opportunities for our people and positions us well to attract the best talent in our industry. This is an exciting time for Zentiva and we are confident that with the support of Advent we can realize our ambition.”
At Zentiva we aspire that healthcare should be a right and not a privilege. More than ever, people need better access to healthcare. Today, the everyday solutions that we all depend on count as a vital foundation of healthy living.
Zentiva works for the people of Europe. Standing side-by-side with healthcare professionals, pharmacists and Health System decision-makers, we have the same sense of social obligation to help lower costs and improve access to healthcare.
With more than 2 500 people across Europe and 2 production sites in Prague and Bucharest, we strive to be the champion of Generics and OTC medicines.
For more information, visit: www.zentiva.com
Ines WINDISCH, Head of Corporate Affairs
Zentiva Group, a.s.,
Cell: +420 601 341 444
U Kabelovny 130 – 102 37 PRAGUE – Czech Republic